iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Stock Short Interest Report for October

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 67,932 shares, a decline of 68.9% from the September 30th total of 218,618 shares. Based on an average daily trading volume, of 164,313 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.9% of the company’s shares are sold short.

Institutional Trading of iShares Genomics Immunology and Healthcare ETF

A hedge fund recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Anchor Investment Management LLC acquired a new position in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,898 shares of the company’s stock, valued at approximately $98,000.

iShares Genomics Immunology and Healthcare ETF Trading Up 2.6%

Shares of IDNA stock opened at $42.00 on Wednesday. The company has a market cap of $321.30 million, a PE ratio of 14.76 and a beta of 0.94. The company’s fifty day simple moving average is $40.55 and its 200-day simple moving average is $32.99. iShares Genomics Immunology and Healthcare ETF has a 52 week low of $24.29 and a 52 week high of $43.44.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.